Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chimeric Antigen Receptor T-cell”

789 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 789 results

Very early researchUnknownNCT04186052
What this trial is testing

Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma

Who this might be right for
Multiple Myeloma
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Very early researchActive Not RecruitingNCT06574958
What this trial is testing

Clinical Study of CD38\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple Myeloma

Who this might be right for
ORR,OS,PFS
The Second Hospital of Shandong University 10
Early research (Phase 1)Study completedNCT02765243
What this trial is testing

Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma

Who this might be right for
NeuroblastomaEffects of Immunotherapy
Zhujiang Hospital 12
Early research (Phase 1)Looking for participantsNCT04881240
What this trial is testing

Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia, RefractoryPediatric ALL
St. Jude Children's Research Hospital 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT05767359
What this trial is testing

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

Who this might be right for
Multiple MyelomaSmoldering Multiple Myeloma
Dana-Farber Cancer Institute 20
Testing effectiveness (Phase 2)Looking for participantsNCT06589089
What this trial is testing

Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy

Who this might be right for
Diffuse Large B Cell Lymphoma
Ruijin Hospital 18
Early research (Phase 1)UnknownNCT02186860
What this trial is testing

Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia
Affiliated Hospital to Academy of Military Medical Sciences 5
Early research (Phase 1)UnknownNCT05640713
What this trial is testing

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Who this might be right for
Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
Henan Cancer Hospital 12
Early research (Phase 1)UnknownNCT04250324
What this trial is testing

Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma

Who this might be right for
Large B-cell Lymphoma
Shanghai Cell Therapy Group Co.,Ltd 21
Early research (Phase 1)UnknownNCT02930993
What this trial is testing

Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors

Who this might be right for
Mesothelin Positive Tumors
China Meitan General Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT05393804
What this trial is testing

Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center 32
Early research (Phase 1)Not Yet RecruitingNCT07390539
What this trial is testing

B7-H3.CD28Z.CART in CNS Neoplasms

Who this might be right for
Central Nervous System NeoplasmsBrain TumorBrain Tumor, Recurrent+11 more
Robbie Majzner 70
Testing effectiveness (Phase 2)Looking for participantsNCT04186520
What this trial is testing

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Who this might be right for
Non Hodgkin Lymphoma (NHL)Mantle Cell Lymphoma (MCL)Chronic Lymphocytic Leukemia (CLL)+5 more
Medical College of Wisconsin 100
Very early researchUnknownNCT04767308
What this trial is testing

Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Who this might be right for
CD5+ Relapsed/Refractory Hematopoietic MalignanciesChronic Lymphocytic Leukemia (CLL)Mantle Cell Lymphoma (MCL)+3 more
Huazhong University of Science and Technology 18
Early research (Phase 1)UnknownNCT03767725
What this trial is testing

Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma in Relapse
Shenzhen Second People's Hospital 10
Large-scale testing (Phase 3)Ended earlyNCT05664217
What this trial is testing

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Who this might be right for
Non-Hodgkin LymphomaRelapsed/Refractory Diffuse Large B-cell Lymphoma
Nektar Therapeutics 15
Early research (Phase 1)WithdrawnNCT04093648
What this trial is testing

T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)

Who this might be right for
Hepatocellular CarcinomaHepatoblastoma
Baylor College of Medicine
Early research (Phase 1)Looking for participantsNCT06865664
What this trial is testing

FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma

Who this might be right for
Rhabdomyosarcoma
National Cancer Institute (NCI) 50
Early research (Phase 1)Looking for participantsNCT07361094
What this trial is testing

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

Who this might be right for
Relapsed/Refractory Systemic Lupus ErythematosusRelapsed/Refractory Systemic SclerosisRelapsed/Refractory Idiopathic Inflammatory Myopathies+3 more
Beijing Boren Hospital 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT06093841
What this trial is testing

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

Who this might be right for
Lymphoma, Large B-Cell, DiffuseFollicular Lymphoma Grade 3BHigh-grade B-cell Lymphoma+1 more
Shanghai Ming Ju Biotechnology Co., Ltd. 46
Load More Results